RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Eiger BioPharmaceuticals Equity 2024

Eiger BioPharmaceuticals Equity

-14.46 M USD

Eiger BioPharmaceuticals Dividend yield

Ticker

EIGR

ISIN

US28249U1051

WKN

A2AF9X

In 2024, Eiger BioPharmaceuticals's equity was -14.46 M USD, a -126.14% increase from the 55.3 M USD equity in the previous year.

Eiger BioPharmaceuticals Aktienanalyse

What does Eiger BioPharmaceuticals do?

Eiger BioPharmaceuticals Inc is a US biopharmaceutical company that specializes in developing therapeutics for rare and serious diseases. It was founded in 2008 and is headquartered in Palo Alto, California. The company's history is closely tied to the discovery of hepatitis C medications, and their business model focuses on developing antiviral therapies for rare and severe diseases. They have multiple divisions dedicated to different therapeutic areas, including hepatitis C, hepatitis D, fibrosis, and lysosomal storage disorders. They currently offer several products, including Zokinvy for chronic hepatitis C infection and Lambda for hepatitis D. They have also formed strategic partnerships with other pharmaceutical companies to support the development and commercialization of their products. Overall, Eiger BioPharmaceuticals Inc is known for its innovative approach and commitment to improving treatment options for patients with serious medical needs. Eiger BioPharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Eiger BioPharmaceuticals's Equity

Eiger BioPharmaceuticals's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Eiger BioPharmaceuticals's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Eiger BioPharmaceuticals's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Eiger BioPharmaceuticals's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Eiger BioPharmaceuticals’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Eiger BioPharmaceuticals Stock

What is the equity of Eiger BioPharmaceuticals this year?

Eiger BioPharmaceuticals has equity of -14.46 M USD this year.

What was the equity of Eiger BioPharmaceuticals compared to the previous year?

The equity of Eiger BioPharmaceuticals has increased/decreased by -126.14% decreased compared to the previous year.

What impact does a high equity have on investors of Eiger BioPharmaceuticals?

A high equity is advantageous for investors of Eiger BioPharmaceuticals as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Eiger BioPharmaceuticals?

A low equity can be a risk for investors of Eiger BioPharmaceuticals, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Eiger BioPharmaceuticals affect the company?

An increase in equity of Eiger BioPharmaceuticals can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Eiger BioPharmaceuticals affect the company?

A reduction in equity of Eiger BioPharmaceuticals can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Eiger BioPharmaceuticals?

Some factors that can affect the equity of Eiger BioPharmaceuticals include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Eiger BioPharmaceuticals so important for investors?

The equity of Eiger BioPharmaceuticals is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Eiger BioPharmaceuticals take to change the equity?

To change equity, Eiger BioPharmaceuticals can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Eiger BioPharmaceuticals pay?

Over the past 12 months, Eiger BioPharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Eiger BioPharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Eiger BioPharmaceuticals?

The current dividend yield of Eiger BioPharmaceuticals is .

When does Eiger BioPharmaceuticals pay dividends?

Eiger BioPharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Eiger BioPharmaceuticals?

Eiger BioPharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Eiger BioPharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Eiger BioPharmaceuticals located?

Eiger BioPharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Eiger BioPharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Eiger BioPharmaceuticals from 6/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/1/2024.

When did Eiger BioPharmaceuticals pay the last dividend?

The last dividend was paid out on 6/1/2024.

What was the dividend of Eiger BioPharmaceuticals in the year 2023?

In the year 2023, Eiger BioPharmaceuticals distributed 0 USD as dividends.

In which currency does Eiger BioPharmaceuticals pay out the dividend?

The dividends of Eiger BioPharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Eiger BioPharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Eiger BioPharmaceuticals

Our stock analysis for Eiger BioPharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Eiger BioPharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.